Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Dendreon FDA Deadline Set For May 1
|
Luke Timmerman |
11/20/09 |
Seattle
|
|
ImmunoGen Nabs $1M From Amgen
|
Luke Timmerman |
11/19/09 |
Boston
|
|
Paul Allen Diagnosed with Cancer
|
Luke Timmerman & Gregory T. Huang |
11/16/09 |
Seattle
|
|
Trubion CEO Peter Thompson Steps Down, Arch’s Gillis To Step Up Temporarily
|
Luke Timmerman |
11/16/09 |
Seattle
|
|
Oncothyreon Advances Cancer Drug
|
Luke Timmerman |
11/12/09 |
Seattle
|
|
Alder’s Breakout $1B Deal, Kineta Teams With UW on Vaccines, Verathon Gets Acquired, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/12/09 |
Seattle
|
|
Aileron’s New Class of Drugs Shown to Get Inside Cells to Block Prime Cancer Target
|
Luke Timmerman |
11/11/09 |
Boston
|
|
Clearwire Closes $1.5B, Alder Scores $1B Partnership, Software Financings Are Down, & More Seattle-Area Deals News
|
Gregory T. Huang |
11/10/09 |
Seattle
|
|
Who Will Create the Future of San Diego Biotech? Xconomy Event Will Gather Star Innovators From Inside and Outside the Region
|
Luke Timmerman |
11/10/09 |
San Diego
|
|
BioVex Nails Down Another $30M To Finish Pivotal Study of Cancer-Killing Virus
|
Luke Timmerman |
11/10/09 |
Boston
|
|
Tokai Pushes Edge With Three-Pronged Attack on Prostate Cancer
|
Luke Timmerman |
11/10/09 |
Boston
|
|
Dendreon Burns $28M in Q3
|
Luke Timmerman |
11/09/09 |
Seattle
|
|
SpectraScience Raises $4.3M
|
Bruce V. Bigelow |
11/06/09 |
San Diego
|
|
Gloucester Pharma Wins FDA Approval of Drug for Rare Skin Cancer
|
Luke Timmerman |
11/05/09 |
Boston
|
|
Light Sciences Oncology Lines Up Extra $35M Financing For Targeted Cancer Treatment
|
Luke Timmerman |
11/05/09 |
Seattle
|
|
Dendreon Files FDA Application, DxBox Reaches Turning Point, ISB to Do 100 Genomes, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/05/09 |
Seattle
|
|
Calypso Teams Up with Siemens
|
Gregory T. Huang |
11/03/09 |
Seattle
|
|
On-Q-ity Raises $21M in A Round for Personalized Cancer Testing
|
Ryan McBride |
11/03/09 |
Boston
|
|
Dendreon Files Provenge Application to FDA Ahead of Schedule, Now It’s Time to Wait
|
Luke Timmerman |
11/02/09 |
Seattle
|
|
Virdante Pharma Lands $30M in A Round to Combat Inflammation
|
Ryan McBride |
10/29/09 |
Boston
|
|
TEDMED Sessions Seek the Patterns in Health Care and Life Sciences That Hold Ideas Together
|
Bruce V. Bigelow |
10/28/09 |
San Diego
|
|
Nuclea Nabs $3.4M Deal
|
Luke Timmerman |
10/22/09 |
Boston
|
|
Five Red Flags of a Biotech, Pathway Medical Learns Lessons, Amgen Faces FDA Delay, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/22/09 |
Seattle
|
|
Antigenics Shares Plummet as Cancer Vaccine Application Rejected in Europe
|
Luke Timmerman |
10/21/09 |
Boston
|
|
Augmenix Snags $6.1M
|
Luke Timmerman |
10/19/09 |
Boston
|
|
Calistoga Cancer Drug Shows “Encouraging” Preliminary Results in Small Study
|
Luke Timmerman |
10/19/09 |
Seattle
|
|
Top 10 Highlights from FiReGlobal: Michael Dell, Lee Hartwell, Irwin Jacobs, and More
|
Gregory T. Huang |
10/16/09 |
Seattle
|
|
Dendreon Recruits Aces to Board, Amgen Seeks to Raise Hit Rate, Lee Hood Startup Gets $30M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/15/09 |
Seattle
|
|
Five Red Flags to Watch Out For in a Biotech, From Dendreon Co-Founder Chris Henney
|
Luke Timmerman |
10/15/09 |
Seattle
|
|
New Life Sciences Startup Shows UCSD Technology Can Boost Immune Response to Cancer in Mice
|
Bruce V. Bigelow |
10/14/09 |
San Diego
|
|
Page 1 of
15 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
